4.6 Article

Diverse Regulation of Claudin-1 and Claudin-4 in Atopic Dermatitis

期刊

AMERICAN JOURNAL OF PATHOLOGY
卷 185, 期 10, 页码 2777-2789

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2015.06.021

关键词

-

资金

  1. MFF Tirol grant [194]
  2. Rene Touraine Foundation
  3. Dutch Technology Foundation Stichting Technische Wetenschappen (STW) grant [10703]
  4. Landes-Offensive zur Entwicklung Wissenschaflich-okonomischer Exzellenz (LOEWE)
  5. ERA-Net for Research Programmes on Rare Diseases, E-Rare-2 [01GM1201]
  6. Deutsche Forschungsgemeinschaft [Forschergruppe 721/2, BR-1982-4-1]

向作者/读者索取更多资源

Tight junctions are important for skin barrier function. The tight junction protein claudin 1 (Ctdn-1) has been reported to be down-regulated in nontesional skin of atopic dermatitis (AD) patients. In contrast, we did not observe a significant down-regulation of Ctdn-1 in nonlesional skin of the AD cohort used in this study. However, for the first time, a significant down-regulation of Cldn-1 in the upper and Lower epidermal Layers of lesional skin was detected. In addition, there was a significant up-regulation of Cldn-4 in nonlesional, but not lesional, AD skin. For occludin, no significant alterations were observed. In an AD-Like allergic dermatitis mouse model, Cldn-1 down-regulation in eczema was significantly influenced by dermal inflammation, and significantly correlated with hallmarks of eczema (ie, increased keratinocyte proliferation, altered keratinocyte differentiation, increased epidermal thickness, and impaired barrier function). In human epidermal equivalents, the addition of IL-4, IL-13, and IL-31 resulted in a down-regulation of Cldn-1, and Cldn1 knockdown in keratinocytes resulted in abnormal differentiation. In summary, we provide the first evidence that Cldn-1 and Cldn-4 are differentially involved in AD pathogenesis. Our data suggest a role of Cldn-1 in AD eczema formation triggered by inflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据